Mydane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

The formulation contains lidocaine, which blocks sodium channels to numb ocular nerves; phenylephrine, an α1‑adrenergic agonist that contracts the dilator pupillae muscle causing pupil dilation; and tropicamide, a muscarinic antagonist that relaxes the sphincter pupillae muscle, enhancing cycloplegia and mydriasis. Together they achieve anesthesia and sustained dilation.

The dose of Mydane is determined by the operating ophthalmologist based on the specific surgical protocol and patient factors. The prescriber selects the appropriate volume and concentration for intracameral injection at the time of surgery.

Safety data for Mydane in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mydane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Mydane combines a local anesthetic (lidocaine) with two mydriatic agents (phenylephrine and tropicamide) in a single injection, offering both anesthesia and sustained dilation. Alternative regimens may require separate administrations of anesthetic drops and mydriatics, potentially increasing procedure time. Mydane’s triple‑action formulation can simplify workflow and provide more consistent pupil control.

Mydane should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Mydane is administered by intracameral injection directly into the anterior chamber of the eye during surgery. The injection is performed by the operating ophthalmologist using aseptic technique and the appropriate volume as dictated by the surgical protocol.

Serious risks include severe allergic reactions (anaphylaxis), persistent high intra‑ocular pressure, corneal edema or ulceration, endophthalmitis, and systemic cardiovascular effects such as arrhythmias or hypertensive crisis due to phenylephrine absorption. Immediate medical attention is required if any of these occur.

Mydane should be avoided in patients with known hypersensitivity to any of its components, uncontrolled hypertension, significant cardiac arrhythmias, active ocular infection, or in those where pupil dilation is contraindicated. The prescribing clinician must evaluate each patient’s medical history before use.